Therapeutic drug monitoring of oral targeted antineoplastic drugs
A Mueller-Schoell, SL Groenland… - European journal of …, 2021 - Springer
Purpose This review provides an overview of the current challenges in oral targeted
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …
Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs
RJ Brüggemann, R Verheggen, E Boerrigter… - The Lancet …, 2022 - thelancet.com
Over the past 10 years, the number of targeted therapies for haematological malignancies
has substantially increased, and many new drugs have entered the market. Many of these …
has substantially increased, and many new drugs have entered the market. Many of these …
Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer
Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in
patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two …
patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two …
Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments
SK Agarwal, CD DiNardo, J Potluri, M Dunbar… - Clinical Therapeutics, 2017 - Elsevier
Purpose The effect of posaconazole, a strong cytochrome P450 3A (CYP3A) inhibitor and
commonly used antifungal agent, on the pharmacokinetic properties of venetoclax, a CYP3A …
commonly used antifungal agent, on the pharmacokinetic properties of venetoclax, a CYP3A …
Pharmacokinetics of venetoclax, a novel BCL‐2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non‐Hodgkin lymphoma
Venetoclax is a selective BCL‐2 inhibitor that is approved in the United States for the
treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have …
treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have …
Statins enhance efficacy of venetoclax in blood cancers
Statins have shown promise as anticancer agents in experimental and epidemiologic
research. However, any benefit that they provide is likely context-dependent, for example …
research. However, any benefit that they provide is likely context-dependent, for example …
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma
Aims To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole,
on the pharmacokinetics, safety and tolerability of venetoclax. Methods Twelve patients with …
on the pharmacokinetics, safety and tolerability of venetoclax. Methods Twelve patients with …
Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial
Purpose: This global phase I trial investigated the safety, efficacy, pharmacokinetics, and
pharmacodynamics of lisaftoclax (APG-2575), a novel, orally active, potent selective B-cell …
pharmacodynamics of lisaftoclax (APG-2575), a novel, orally active, potent selective B-cell …
[HTML][HTML] Precision dosing: public health need, proposed framework, and anticipated impact
“Precision dosing” focuses on the individualization of drug treatment regimens based on
patient factors known to alter drug disposition and/or response. In 2015, over 8 in 10 …
patient factors known to alter drug disposition and/or response. In 2015, over 8 in 10 …
Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics classification system IV compound—the …
AE Riedmaier, DJ Lindley, JA Hall… - Journal of …, 2018 - Elsevier
Venetoclax, a selective B-cell lymphoma-2 inhibitor, is a biopharmaceutics classification
system class IV compound. The aim of this study was to develop a physiologically based …
system class IV compound. The aim of this study was to develop a physiologically based …